Document Detail


Viscosupplementation with high molecular weight native hyaluronan. Focus on a 1500-2000 KDa fraction (Hyalubrix®).
MedLine Citation:
PMID:  25487947     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: Joint disease reduces the rheological properties of synovial fluid, increasing the susceptibility of the articular cartilage to damage. Thus, a therapeutic strategy, called viscosupplementation, was proposed in which intra-articular injections of a suitable material are used to restore the viscoelastic properties of the synovial fluid. Solutions of high-MW native HA, which is the main component of the synovial fluid, were a natural choice to reach this goal, but HA-derived materials, engineered to achieve greater elastoviscosity and intra-articular residence time, were also developed. In the last twenty years the clinical experience showed that viscosupplementation is effective in joint diseases such as osteoarthritis, with beneficial effects on pain, function and patient global assessment. However, a marked variability between different preparations on different outcome parameters was reported to exist.
AIM: In the present paper the available data on Hyalubrix®, a specific 1.5% formulation of natural HA with MW in the range 1500-2000 kDa, were reviewed, trying to outline, in the framework of the available intra-articular therapies, the role it can play for the symptomatic management of patients with degenerative joint arthropathy.
Authors:
D Guidolin; F Franceschi
Related Documents :
14630567 - Effect of an anti-pdgf-beta-receptor-blocking antibody on restenosis in patients underg...
19620857 - Three-year prognosis of japanese patients with st-elevation myocardial infarction treat...
24508777 - The impact of knee instability with and without buckling on balance confidence, fear of...
17419097 - Contemporary treatment of in-stent restenosis and the incidence of recurrent in-stent r...
3327637 - Systemic antibiotic prophylaxis and reconstructive ear surgery.
6688767 - Outcome of patients with graves' disease after long-term medical treatment guided by tr...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European review for medical and pharmacological sciences     Volume:  18     ISSN:  2284-0729     ISO Abbreviation:  Eur Rev Med Pharmacol Sci     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-12-09     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9717360     Medline TA:  Eur Rev Med Pharmacol Sci     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  3326-38     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lycopene prevents experimental priapism against oxidative and nitrosative damage.
Next Document:  Ergothioneine produces relaxation in isolated rat aorta by inactivating superoxide anion.